Intracerebral administration of a modified antisense oligonucleotide targeting the dopamine system in a mouse model of Parkinson’s disease

STAR Protocols

Lluis Miquel-Rio¹  Leticia Campa²  Analia Bortolozzi³  Rubén Pavia-Collado⁴ 

[1] August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;Biomedical Research Networking Center for Mental Health (CIBERSAM), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain;miCure Therapeutics LTD., 6423902 Tel-Aviv, Israel;Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), 08036 Barcelona, Spain;

关键词: Cell Biology;    Health Sciences;    Model Organisms;    Neuroscience;    Protein Biochemistry;   

DOI  :  

来源: DOAJ

【 摘 要 】

Summary: Here, we present an optimized protocol for generating a mouse model overexpressing human α-synuclein in dopamine (DA) neurons driven by an adeno-associated viral (AAV) vector and for the examination of the benefit of an antisense oligonucleotide (ASO)-based therapy on DA neurotransmission under Parkinson’s disease (PD)-like conditions. We describe AAV injection, followed by implantation of an osmotic minipump for ASO delivery and a guide cannula for microdialysis to measure DA release. This protocol can be used to evaluate oligonucleotide-based therapies for PD.For complete details on the use and execution of this protocol, please refer to Alarcón-Arís et al. (2020). : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.

【 授权许可】

Unknown